Up to half of the patients diagnosed with CM carry activating mutations in the serine-threonine kinase of the BRAF gene (BRAF-V600), with almost a quarter of patients (15–25%) carrying mutations in the RAS gene (Q61R, Q61K), which downstream activate RAF, MEK, and ERK. This evidence concerns the gene BRAF and cutaneous mastocytosis.